| Description | Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests. |
| In vivo | In an inhaled lipopolysaccharide (LPS)-induced ARDS mouse model, BAY-1834845 downregulated genes more efficiently than dexamethasone, especially TNF, IL-17, interferon, and Toll-like receptor signaling[1]. |
| Target activity | IRAK4:3.55 nM |
| Synonyms | BAY 1834845 |
| molecular weight | 470.47 |
| Molecular formula | C20H21F3N4O4S |
| CAS | 1931994-81-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 112.5 mg/mL (239.1 mM), Sonication and heating to 60℃ are recommended. |
| References | 1. Li Q, et al. Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459. |